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The heterogeneity of myelodysplastic syndromes (MDSs)
has made evaluating patient response to treatment
challenging. In 2006, the International Working Group
(IWG) proposed a revision to previously published
standardized response criteria (IWG 2000) for uni-
formly evaluating clinical responses in MDSs. These
IWG 2006 criteria have been used prospectively in
many clinical trials in MDSs, but proved challenging in
several of them, especially for the evaluation of ery-
throid response. In this report, we provide rationale for
modifications (IWG 2018) of these recommendations,
mainly for “hematological improvement” criteria used for
lower-risk MDSs, based on recent practical and reported
experience in clinical trials. Most suggestions relate to
erythroid response assessment, which are refined in an
overall more stringent manner. Two major proposed
changes are the differentiation between “procedures”
and “criteria” for hematologic improvement–erythroid
assessment and a new categorization of transfusion-
burden subgroups. (Blood. 2019;133(10):1020-1030)
Introduction
Myelodysplastic syndromes (MDSs) are disorders in which he-
matopoietic stem cells do not mature into healthy blood cells,
leading to cytopenias, most commonly anemia. Anemia-related
symptoms such as fatigue are generally the most commonly
reported symptoms in MDSs1-3 and ;50% of patients with MDSs
require regular red blood cell (RBC) transfusions.4 Although RBC
transfusions provide short-term symptomatic benefit, they cannot
correct most aspects of health-related quality of life (QoL), they
contribute to iron overload, and they consume substantial human
as well as financial resources.5
Anemia associated with MDSs is therefore routinely treated
by erythropoiesis-stimulating agents (ESAs), or lenalidomide in
lower-risk MDSs with isolated del(5q), and by hypomethylating
agents (HMAs) in higher-risk disease, whereas novel compounds
are currently under clinical development. Thrombocytopenia
and neutropenia are less frequent than anemia in lower-risk
MDSs and treatment of these cytopenias has proven more dif-
ficult. Thrombopoietic agents are currently undergoing evalua-
tion in patients with thrombocytopenia at risk for bleeding events
or platelet transfusions.
Given the development of new treatments for MDSs, it is important
to standardize response evaluation to allow optimal clinical decision-
making as well as robust comparison of clinical trial data across
studies. Currently, response evaluation is based on criteria proposed
by the International Working Group (IWG) in 2000,6 which were
modified in 20067 and have thus far beenwidely accepted (Table 1).
Clinical experience has shown limitations of those criteria. For
example, studies of HMAs in higher-risk MDSs showed that
restarting HMA cycles on day 29 of the previous cycle usually
prevented complete recovery from cytopenias (especially neu-
tropenia) and therefore precluded fulfillment of complete re-
mission (CR) criteria, even if the bone marrow blast count had
normalized. More recently, the present authors have been in-
volved in the steering committees of various industry and aca-
demic sponsored clinical trials in lower-risk MDSs focusing mainly
on the treatment of anemia (and, in 1 case, thrombocytopenia)
as well as in independent reviews of investigators’ response
assessment in MDS trials. In the context of these assessments,
challenges emerged with regard to evaluating erythroid or plate-
let response when stringently applying IWG 2006 criteria.8-10 A
few illustrative examples of clinical cases will be presented and
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discussed within this manuscript. They all highlight potential
pitfalls in determining a clinical response in a given patient un-
dergoing disease-specific treatment. On the other hand, treatment
of anemia, including its accurate monitoring and assessment, is
crucial for both the general improvement of the QoL of the
patients as well as disease-specific outcomes.11-21
Table 1. Suggested procedures for supporting accurate response evaluation: HI-E
Item Suggested IWG 2018 procedures
IWG 2006
procedures
Baseline assessment procedures
Screening period for the evaluation of
transfusion burden and baseline Hb levels*
16 wk but only in lower-risk MDSs, when anemia is the predominant
or only cytopenia; patients should be off any active treatment
during this period
8 wk
Transfusions: Patients with unusual or abnormal changes of their
transfusion rate during the 16-wk observation period should be
evaluated carefully for confounding factors (ie, bleeding,
hemolysis, EPO levels, iron metabolism), including a potential
extension of the evaluation period
Baseline Hb: For the determination of the baseline Hb level, we
suggest using the mean of all available Hb measurements during
the 16-wk screening period; to avoid bias, measurements prior to
transfusions should be used in this calculation for TD patients and
the measurements should be at least 7 d apart
No./frequency of Hb measurements prior
therapy
Hbmeasurements for the determination of baseline Hb values should
be performed (or retrospective results should be available) at least
every 2 wk, if possible, during the 16 wk screening period
NA
Blood count device/method and laboratory Investigators should be aware of potential fluctuations in Hb
measurements due to different blood count devices or laboratories
NA
To avoid any ambiguities in Hb levels, investigators should check
when using several devices/methods or laboratories whether they
yield similar Hb levels; in case of different values, baseline Hb level
(as well as subsequent response and response duration) should be
assessed based on measurements from only 1 device/method or
laboratory, especially at key time points of a clinical trial
Baseline Hb level Hb , 10 g/dL as prerequisite for patients in need of therapy Hb , 11 g/dL
Response evaluation procedures
Response evaluation period 24 wk 8 wk
No./frequency of Hb measurements Hb measurement should be performed (or results be available) at
least every 2 wk during the first 16 wk of therapy
NA
Blood count device/method and laboratory Investigators should be aware of potential fluctuations in Hb
measurements due to different blood count devices or laboratories
NA
To avoid any ambiguities in Hb levels, investigators should check
when using several devices/methods or laboratories whether they
yield similar Hb levels; in case of different values, baseline Hb level,
response, and response duration should be assessed based on
measurements from only 1 device/method or laboratory,
especially at key time points of a clinical trial
Dose adjustment policy for high Hb levels Treatment should be continued at a lower dose level (ie, increased
intervals between doses or administration of lower dose level)
rather than stopped when 2 subsequent Hbmeasurements exceed
a predefined threshold
NA
If the drug under investigation is being reduced in dose, stopped, or
its administration delayed in a responding patient for protocol-
defined reasons leading to a loss of response, this should not be
counted as such, if reintroduction of the drug at the same or lower
dose induces a new response
If the reintroduction of the drug at a lower dose does not reinduce
a response, this should be documented as such
When the investigational drug is being reduced in dose, stopped, or
its administration delayed, blood counts are required continuously
to monitor subsequent blood levels
NA, not available.
*The 16-wk screening period applies mainly to lower-risk MDSs where anemia is the major cytopenia. Patients with higher-risk MDSs or with severe thrombocytopenia may require
earlier treatment and an 8-wk screening period is acceptable in that situation.
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As a panel of international experts inMDSs, weprovide a proposal
to improve and further develop IWG criteria, focusing on “he-
matological improvement,” that is, improvement of cytopenias in
lower-risk MDSs, especially anemia. The concept of this IWG 2018
consensus is not to define narrow criteria but rather to describe
challenges associated with the current response assessment and
guidelines applicable for most patients included in clinical trials.
Methods
A task force of experts in the field of MDS research in the
European Union (European LeukemiaNet [ELN] and European
Myelodysplastic Syndromes Cooperative Group [EMSCO])
and North America followed the procedures used for the de-
velopment of the current ELN guidelines on MDSs.22 The con-
sensus development was based on review of recent literature on
the topic as well as recent clinical experience, especially in
3 recent randomized trials9,10,23 using drugs (ESA or lenalidomide)
to treat anemia of lower-risk MDSs, which served as a platform to
identify pitfalls of current IWG 2006 guidelines.7 Different clinical
scenarios were prepared, shared and discussed within the panel.
A consensus was considered only when agreement was reached
by more than two-thirds of the experts.
Results
1. Assessment of the erythroid lineage in
MDS patients
1.1. Baseline assessment procedures
1.1.1. Current obstacles in defining RBC transfusion dependence
and independence A reliable characterization of the RBC trans-
fusion burden of MDS patients and its evolution during treat-
ment is crucial, especially in the context of clinical research.
Using current IWG 2006 criteria, anemic MDS patients are catego-
rized in a binary fashion as “transfusion dependent” (TD) and
“transfusion independent” (TID); TD being defined as having re-
ceived at least 4 U of RBCs within 8 weeks for hemoglobin (Hb) of
, 9 g/dL. Hematologic improvement–erythroid (HI-E) in the TID
patients requires anHb improvement of at least 1.5g/dL lasting for at
least 8weeks. HI-E response in patients in the TD category is defined
by IWG 2006 criteria as a reduction of at least 4 U per 8 weeks
transfused for the same Hb threshold (eg, from 8 to 4 U, 6 to
2 U, or 4 to 0 U) (Table 1) and also lasting for at least 8 weeks
(2 months).
This definition is problematic in 2 ways:
1. The screening period for the assessment of transfusion
dependence is not well defined; it is often considered to
be 8 weeks given the above definition for TD. However,
8 weeks is a short period for the objective assessment of
Hb levels, as certain natural or event-driven fluctuations are not
adequately reflected. If fluctuations are, for instance, caused by
intercurrent infections or bleeding events, they are not in-
fluential for the long-term transfusion needs of the patients.
However, for the short-term, nonrecognized bleeding could
lead to wrongly assessed transfusion need.
2. The categorization into the 2 current groups (TD/TID) does
not take into account a large number of patients with low
transfusion burden, that is, receiving transfusions but,4 U of
RBCs within 8 weeks, for whom transfusion elimination is
considered an appropriate therapeutic goal, which is not
reflected by current HI-E criteria.
Therefore, we suggest the following clarification and revisions
within the IWG criteria.
1.1.1.a. Screening period
To illustrate the potential issues generated by the current
screening period of 8 weeks, Figure 1 reflects 5 potential
patients having all received 4 U of RBCs for an Hb of,9 g/dL
within 8 weeks (56 days) prior to a putative day of onset of
a therapeutic agent. According to the IWG 2006 criteria, these
patients would all be considered TD.
However, when the retrospective analysis is extended to 16 weeks
(112 days), the transfusion burden in these 5 patients may differ
meaningfully, as illustrated in Figure 2. Assessing the 16-week pe-
riod across these 5 exemplary patients, only patients 1 and 5 fulfill
IWG2006 criteria of anaveragenumber of at least 2Uof RBCswithin
28days (or 8Uwithin 16weeks).We thus consider having ahistory of
RBC transfusions during the 16 weeks (which could be also part of
the screening period) preceding onset of treatment in a clinical trial
mandatory. This recommendation can, of course, only apply to
lower-riskMDSs,when anemia is thepredominant or only cytopenia.
Indeed, significantly delaying treatment of higher-risk MDSs or in
patients with severe thrombocytopenia would not be acceptable.
As in IWG 2006 criteria, only RBC transfusions administered for
a mean Hb level below 9 g/dL are to be considered (see also
comment in Table 2), which takes into account that a certain
variation (see “1.2.3 Transfusion policy”) can occur. Transfusions
for intercurrent diseases (bleeding, surgical procedure, etc) should
not be considered.
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Figure 1. Transfusion history of 5 hypothetical MDS
patients within 8 weeks. All receiving RBC support for
an Hb of ,9 g/dL for up to 8 weeks (56 days) prior
to day 0, that is, start for a subsequent therapy, for
example, within a clinical trial. The total number of
RBC U within 8 weeks is 4 in all patients (Pat.).
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Panel recommendation
A screening period of 16 weeks before the anticipated
treatment start is mandatory and should be added as
a prerequisite for subsequent IWG response determination
in patients with lower-risk MDSs where anemia is the
predominant or only cytopenia. Patients should be off of
any active treatment during this period.
Note: Patients with unusual or abnormal changes of their
transfusion rate during the 16-week screening period
should be evaluated carefully for confounding factors
(ie, bleeding, hemolysis, erythropoietin [EPO] levels, iron
metabolism), including a potential extension of the eval-
uation period.
1.1.1.b. Transfusion-burden categories
Another issue with the current IWG 2006 criteria, as stated
previously, is that patients transfused ,4 U within 8 weeks (but
receiving regular transfusions) cannot be considered as res-
ponders if they become free of transfusions but without an Hb
improvement of at least 1.5 g/dL after receiving therapy on
a clinical trial. This highlights the particular problem of baseline
Hb-level definition, which fluctuates relative to the time to
previous transfusions. In addition, an important part of this patient
group reaches transfusion independence with new therapeutic
agents compared with patients being transfused .4 U every
8 weeks.24-26
Panel recommendation
Refinement of the RBC transfusion burden by dividing
patients into 3 categories (nontransfused [NTD], low trans-
fusion burden [LTB], and high transfusion burden [HTB]) as
defined in the following sections.
• NTD patients
This category includes patients having received no transfusions
within the screening period of 16 weeks. In these patients, an
increase of Hb (by at least 1.5 g/dL 5 0.9 mmol/L) is the main
goal of therapeutic approaches, as already defined by IWG 2006
criteria. This threshold is based on several studies linking an
improvement of QoL and disease-specific outcomes with Hb
levels.11-21
• LTB patients
This category includes patients who received 3 to 7 RBCs within
the screening period of 16 weeks, on at least 2 different dates/
points in time. In addition, in those patients, we consider achieving
transufsion independence a clinically meaningful end point even
in the absence of an increase of Hb by at least 1.5 g/dL (as defined
by the current IWG 2006 criteria) if there is no modification of the
transfusion policy, especially of the transfusion threshold.
• HTB patients
This third category includes patients with HTB, which is over-
lapping the current IWG 2006 TD cohort, that is, defined by
receiving$8 U of RBCs in 16 weeks (rather than just$4 RBCs in
8 weeks), in at least 2 transfusion episodes.
The coauthors did not fully agree on whether patients who received
only 1 or 2 RBC concentrates during this 16-week period should be
categorized in theNTDor LTBgroup. If such patients are included in
clinical trials evaluating HI-E, it is recommended, however, that HI-E
achievement require not only transfusion independence but also an
increase of Hb by at least 1.5 g/dL (5 0.9 mmol/L) in these patients.
1.1.2. Determination of baseline Hb levels
1.1.2.a. Hb-level threshold
Apart from the definition of transfusion dependence and in-
dependence, another major criterion for the assessment of the
erythroid response is the baseline Hb level, which according to
IWG 2006 has to be,11 g/dL before treatment in NTD patients.
For the determination of the baseline Hb level, we suggest using
the mean of all available Hb measurements during the 16-week
screening period. To avoid bias, measurements prior to trans-
fusions should be used in this calculation for TD patients and the
measurements should be at least 7 days apart.
Panel recommendation
In terms of clinical threshold for a given therapy, we suggest
reducing this from the current ,11 g/dL according to IWG
2006 to ,10 g/dL as patients considered candidates for
clinical trials or specific treatments are rarely symptomatic
above 10 g/dL. This is supported by the fact that the Revised
International Prognostic Scoring System (IPSS-R) also con-
siders 10 g/dL as the threshold having a prognostic impact.27
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Figure 2. Transfusion history of 5 hypothetical MDS patients within 16 weeks. Transfusion history of the same 5 hypothetical MDS patients (Figure 1) but with an extended
period of 16 weeks (112 days) prior to the start of a putative therapy. The total number of RBC U within 8 weeks is ,4 in patients 2, 3, and 4, respectively.
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1.1.2.b. Number and frequency of baseline Hb measurements
To adequately determinate baseline Hb values, it is important
to have a sufficient number of Hb measurements. Statistically
validated data in patients with renal disease suggest that
weekly Hb measurements provide the most reliable monitor-
ing of anemia.28 From this evidence, we recommend frequent
monitoring at regular intervals and believe that, for MDS patients,
a biweekly interval is frequent enough without imposing an un-
reasonable burden on patients and investigators.
Panel recommendation
For the determination of baseline Hb levels, Hb mea-
surements should be performed (or retrospective results
should be available) at least every 2 weeks, if possible,
during the 16-week screening period.
1.1.2.c. Blood count device/method or laboratory for Hb
determination
On a more technical level, the experience of some of the
members of the steering committee involved in recent clinical
trials in lower-riskMDSswas that different hemocytometer devices
sometimes gave different Hb-level results. Similar challenges are
observed when comparing other evaluations in MDSs: for in-
stance, marrow blast counts in the context of morphological
assessments. Results for the same patient and time point can vary
significantly between reviewers. This is why many trials dictate
central morphologic evaluations, at least for the key measure-
ments, such as baseline levels and response-assessment visits. We
recommend that Hb levels should be treated similarly based on
the inconsistency sometimes observed between devices.
Panel recommendation
To avoid any ambiguities in Hb levels when using several
devices/methods or laboratories, investigators should check
whether they yield similar Hb levels. In case of different
values, baseline Hb level, response, and response duration
should be assessed based on measurements from only
1 device/method or laboratory, especially at key time points
of a clinical trial.
1.2. Response evaluation Based on the comments made in the
previous sections, we suggest the following amendments to
IWG 2006 criteria for “hematological improvement.”
1.2.1. Response-evaluation period Similarly, as we propose a
prolonged screening period of 16 weeks to adequately de-
termine the transfusion status of a given patient before starting an
investigational treatment, we suggest that the erythroid re-
sponse should be assessed on an observation period of at
least 16 weeks. Because erythroid response, with any drug, is
often only observed after a certain delay, we consider that, in
these cases, a minimum 24-week period of observation after
treatment onset is required.
In addition, onset of response is not clearly determined using
IWG 2006 criteria. We suggest that response starts when the Hb
level rises by at least 1.5 g/dL in non-TD patients and from the
time point of the anticipated next transfusion (if the patient
remains NTD) in TD patients.
Panel recommendation
We recommend defining an observation period to assess
response of at least 16 to 24 weeks starting directly after
study treatment initiation at week 0. We consider response
to start when the Hb level rises by at least 1.5 g/dL in non-
TD patients and from the date of the anticipated next
transfusion (if the patient remains NTD) in TD patients.
1.2.2. Assessment of HI-E response depending on pretreatment
transfusion burden The 3 newly proposed transfusion-burden
category groups (NTD, LTB, HTB) lead to a need for a more
discriminate response evaluation. In addition, although we
acknowledge that a response duration of at least 8 weeks is
sufficient to consider a patient as responder (especially in early
phase clinical trials), we feel that only a response duration of
at least 16 weeks is clinically meaningful. Response duration
should therefore always be reported.
1.2.2.a. NTD patients (screening period: no RBC transfusion
in 16 weeks)
Response in those patients is assessed solely based on an in-
crease in the Hb level.
Panel recommendation
In terms of required Hb increase to reach HI-E, we do not
suggest modifying the current threshold (Hb increase by at
least 1.5 g/dL). However, we would recommend defin-
ing an HI-E by at least 2 consecutive Hb measurements
$1.5 g/dL, maintained over at least 8 weeks during an
observation period of 16 to 24 weeks (as defined in “1.2.1.
Response-evaluation period”) compared with the mean of
2 Hb measurements within 16 weeks before treatment
onset. Only a response duration of at least 16 weeks, how-
ever, is considered clinically meaningful.
Also, importantly, we acknowledge that, thereafter, natural
fluctuations of Hb levels might be observed irrespective of
continuation of therapy. Therefore, a patient with a drop of
previous Hb level increase below 1.5 g/dL compared with pre-
treatment (but showing an increase of at least 1.0 g/dL) would
still count as a responder. However, drops to levels between
1.0 and 1.5 g/dL are only admitted on a maximum of 2 occasions
over a period of 16 weeks. We recommend that intervals be-
tween blood counts do not exceed 2 weeks.
1.2.2.b. LTB patients (screening period: 3-7 RBCs in 16 weeks)
Panel recommendation
HI-E in LTB patients is defined as follows. Response in LTB
patients corresponds to transfusion independence, defined
by the absence of any transfusions in a period of at least
8 weeks during an observation period of 16 to 24 weeks with
the same transfusion policy (defined in “1.2.4. Transfusion
policy”) compared with 16 weeks prior to treatment. Only
response duration of at least 16 weeks, however, is con-
sidered clinically meaningful.
Again, we want to highlight that these responses can occur in the
absence of an increase of Hb by at least 1.5 g/dL 5 0.9 mmol/L
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(former IWG 2006) but must not be associated with a decrease in
Hb from baseline.
1.2.2.c. HTB patients (screening period: ‡8 RBCs in 16 weeks)
Panel recommendation
HI-E in HTB patients is defined as follows.
Major response: Major HI-E response in HTB patients cor-
responds to transfusion independence, defined by the ab-
sence of any transfusions over a period of a minimum of
8 weeks within an observation period of 16 to 24 weeks with
the same transfusion policy (defined in “1.2.4. Transfusion
policy”) compared with 16 weeks prior to treatment. Only
a response duration of at least 16 weeks, however, is con-
sidered clinically meaningful.
Minor response: Minor HI-E response in HTB patients is
defined as a reduction by at least 50% of RBCs over
a minimum of 8 weeks with the same transfusion policy
(defined in “1.2.4. Transfusion policy”) compared with
16 weeks prior to treatment. Only a response duration of at
least 16 weeks, however, is considered clinically meaningful.
Again, we want to highlight that the above responses can occur
in the absence of an increase of Hb by at least 1.5 g/dL 5
0.9 mmol/L (former IWG 2006) but must not be associated with
a decrease in Hb from baseline.
In LTB and HTB patients who achieve transfusion independence,
the duration of transfusion independence (eg, number of pa-
tients with 8 weeks vs 24 weeks of continuous transfusion
independence) as well as the magnitude of increase in mean Hb
values should also be reported (by dose, by drug, etc) to better
assess the therapeutic potential of a specific treatment.
1.2.2.d. Patients having received 1 or 2 RBC concentrates
during the screening period
As stated in “HTB patients,” some coauthors did not fully agree
on whether patients who received only 1 or 2 RBC concentrates
during the 16-week screening period should be categorized in
the NTB or LTB group. If such patients are included in clinical
trials evaluating HI-E, it is recommended that HI-E achievement
requires not only transfusion independence but also an increase
of Hb by at least 1.5 g/dL (50.9 mmol/L).
1.2.3. Number and frequency of Hb measurements for response
determination As mentioned in “1.1.2. b. Number and fre-
quency of baseline Hb measurements,” we suggest biweekly
intervals for the assessment of response and its duration.
Panel recommendation
Hbmeasurement should be performed or results should be
available at least every 2 weeks during the first 16 weeks of
therapy.
1.2.4. Transfusion policy The proposed more stringent defi-
nitions of transfusion-burden categories may lead to the fact that
changes in transfusion policy can have an even more important
impact on response compared with current IWG 2006 criteria.
Especially in LTB patients, where transfusion independence is the
criterion for response, predefined transfusion policies (eg, in terms
of Hb threshold for transfusing) must be maintained to avoid bias
and distorted response evaluations.
Panel recommendation
We therefore recommend incorporating, as a new pre-
requisite for an unbiased response evaluation, the main-
tenance of a comparable transfusion policy on therapy as
compared with the 16-week screening period. For example,
patients transfused below a certain threshold (eg, 8.5 g/dL)
before therapy should receive transfusions at the same
threshold on study, unless an exceptional circumstance
requires this threshold to be punctually changed (documen-
tation by the treating physician will be required). We suggest
a maximum variation between pre- and on-study practice of
1 g/dL (or 0.6 mmol/L) in terms of transfusion threshold.
Exceptions to this rulemay be accepted in cases of well-documented
moderate or severe angina pectoris, cardiac or pulmonary insuffi-
ciency, or ischemic neurologic diseases. In these cases, a higher
transfusion trigger level may be established for an individual patient.
These patients may require special attention when analyzing
responses within clinical trials. Transfusions for intercurrent diseases
(bleeding, surgical procedure, etc) should not be taken into account.
1.2.5. Impact of blood count device/method or laboratories on
response evaluation Response evaluation for a given patient
should be based on only 1 device if discrepancies for the Hb level
are seen between different laboratories or devices (Figure 3).
This is also mandatory for determining responses in other
lineages (hematologic improvement platelet [HI-P], hematologic
improvement neutrophil [HI-N]).
Panel recommendation
Investigators should be aware of potential fluctuations in
Hb measurements due to different blood count devices/
methods or laboratories. Responses and their duration
should be evaluated based on blood counts performed in
the same laboratory or with the same technique if such
fluctuations are observed.
1.2.6. Dose-adjustment policy for blood counts on treatment
Mainly based on the indication in chronic renal failure, avoiding
increases of Hb levels above 12 g/dL29 during treatment with ESA
is recommended in many countries (especially in Europe). In most
clinical trials, this rule is strictly enforced and, once a patient
presents with Hb $ 12 g/dL, therapy has to be stopped and
restarted at a lower dose. Figure 4 illustrates a clinical example.
Deciding on drug interruption and subsequent dose reduction
based on 1 Hb measurement $ 12 g/dL might lead to undesired
Hb decrease, which can hardly be regained by continuation of the
treatment at a lower dose level. The authors believe that dose
reductions should be performed only if 2 subsequent measure-
ments exceed the predefined threshold, whichmay vary according
to different protocols. To maintain response, treatment should
not be stopped but continued at a lower dose level (ie, increased
intervals between doses or lower dose level). A maximum of
2 consecutive Hb values below the response threshold are allowed
in cases of protocol-defined dose adjustments or delays. On the
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contrary, further increase of the Hb levels, even with dose re-
duction, should lead to further dose reduction to avoid potential
thrombotic events.
Panel recommendation
If the drug under investigation is stopped or its dose re-
duced in a responding patient for protocol-defined reasons
leading to a loss of response, this should not be counted as
such if reintroduction of the drug at the same or lower dose
induces a new response. If reintroduction of the drug at
a lower dose does not reinduce a response, this should be
documented as such.
2. Response evaluation for platelets
and neutrophils
Current response definitions for other lineages than the ery-
throid are provided in Table 3. The authors agree that these
reflect clinically meaningful end points. For platelet response,
we suggest leaving the current criteria with additional mod-
ifications for bleeding symptoms and dose reductions. The latter
should only be performed if the platelet count exceeds the
normal range (450 3 109/L) in 2 consecutive blood counts in
order to avoid sharp decreases of platelet counts thereafter.
Furthermore, we suggest reporting increments of neutrophils
and platelets also for patients with a pretreatment absolute
neutrophil count (ANC) of ,1.0 3 109/L and pretreatment
platelet counts of ,100 3 109/L. This is because responses in
patients with an ANC of $1.0 3 109/L and a platelet count of
$100 3 109/L might reflect a multilineage response of certain
drugs (eg, an agent considered to target anemia only, like
luspatercept or sotatercept) and also translate into a better
outcome for patients due to improvement of neutrophil and
platelet number and function.
Challenges in terms of achieving response under treatment
with HMA need to be taken into account as it is known that HMAs
can prevent recovery from cytopenias (especially neutropenia).
3. Progression or relapse after
hematologic improvement
In the current IWG 2006 criteria, progression or relapse after HI
are defined as at least a 50% decrement from maximum re-
sponse levels in neutrophils or platelets, a reduction in Hb by
$1.5 g/dL, and/or recurrence of transfusion dependence. The
authors agree with these criteria but suggest somemodifications
in platelet and neutrophil response. We believe that a patient
with an HI-P of, for example, 30 3 109/L to 300 3 109/L and
a subsequent dip to 140 3 109/L, reflecting at least 50% dec-
rement, is still a responder. The same is true for neutrophils (eg,
from 4 3 109/L to 1.5 3 109/L).
11
6
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10
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Hb
8.5
10
device 1 device 2
Therapy with e.g. ESA
Figure 3. Hbmeasurements with 2 different devices or laboratories at different
points in time in 1 patient treated, for example, with ESA. The figure illustrates
that certain fluctuations of Hb values might be simply a result of differences in the
accuracy of blood devices/methods. An Hb increase by $1.5 g/dL is achieved
constantly only with device 1, which was also used during screening.
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Figure 4. Undesired effects of dosing interruption. The
figure shows the undesired effects of dosing interruption
followed by dose reduction in a patient responding to ESA
therapy and reaching an Hb $ 12 g/dL (starting from a
baseline Hb of 8.5 g/dL). The lower line marks the IWG 2006
response (8.5-10 g/dL) and upper line the general Hb cutoff
for dose interruption in many clinical trials (12 g/dL).
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Table 2. Suggested modified IWG 2018 HI-E criteria for response evaluation
Item Suggested IWG 2018 criteria IWG 2006 criteria
Baseline criteria
Definition of transfusion-
burden categories
3 groups:
NTD (0 RBCs in 16 wk)*
LTB (3-7 RBCs in 16 wk in at least 2 transfusion episodes,
maximum 3 in 8 wk)*
HTB ($8 RBCs in 16 wk, $4 in 8 wk)
2 groups:
TD (at least 4 U of RBC with 8 wk for Hb , 9 g/dL)
TID (,4 U of RBC with 8 wk for Hb , 9 g/dL)
Pretreatment RBC
transfusion policy
Transfusion policy for the individual patient prior to therapy
should be maintained on treatment†
Transfusion threshold of 9 g/dL, no exception for
clinical indication
Response evaluation criteria:
HI-E
NTD (0 RBCs in 16 wk)* At least 2 consecutive Hb measurements $1.5 g/dL for
a period of minimum 8 wk in an observation period of
16 to 24 wk compared with the lowest mean of 2 Hb
measurements (apart from any transfusion) within 16 wk
before treatment onset‡; only a response duration of at
least 16 wk, however, is considered clinically meaningful
Hb increase by 1.5 g/dL and/or relevant reduction of
U of RBC transfusions by an absolute number of at
least 4 RBC transfusions/8 wk compared with the
pretreatment transfusion number in the previous
8 wk; only RBC transfusions given for an Hb of
#9.0 g/dL pretreatment will count in the RBC
transfusion response evaluationLTB (3-7 RBCs in 16 wk in
at least 2 transfusion
episodes, maximum 3 in
8 wk)*
HI-E in LTB patients corresponds to transfusion
independence, defined by the absence of any
transfusions for at least 8 wk in an observation period
of 16-24 wk with the same transfusion policy (defined
below) compared with 16 wk prior to treatment; only
a response duration of at least 16 wk, however, is
considered clinically meaningful
HTB ($8 RBCs in 16 wk,
$4 in 8 wk)
Major response: Major HI-E response in HTB patients
corresponds to transfusion independence, defined by
the absence of any transfusions over a period of
minimum 8 wk in an observation period of 16-24 wk with
the same transfusion policy (defined below) compared
with 16 wk prior to treatment; only a response duration
of at least 16 wk, however, is considered clinically
meaningful
Minor response: Minor HI-E response in HTB patients
is defined as a reduction by at least 50% of RBCs
over a minimum of 16 wk with the same transfusion
policy (defined below) compared with 16 wk prior to
treatment
On-treatment RBC
transfusion policy§
Transfusion policy for the individual patient prior to therapy
should be maintained on treatment if not otherwise
clinically indicated (documentation by the treating
physician required); we suggest a maximum variation
between pre- and on-study practice of 1 g/dL (or
0.6 mmol/L) in terms of transfusion threshold
Transfusion threshold of 9 g/dL, no exception for
clinical indication
Dose adjustment thresholds
for high Hb levels
If the drug under investigation is stopped or its dose
reduced in a responding patient for protocol-defined
reasons leading to a loss of response, this should not
be counted as such if reintroduction at the same or
lower dose of the drug induces a new response; if
reintroduction of the drug at a lower dose does not
reinduce a response, this should be documented as such
NA
Abbreviations are explained in Table 1.
*The coauthors did not fully agree on whether patients who received only 1 or 2 RBC concentrates during the 16-wk screening period should be categorized in the NTB or LTB group. If
such patients are included in clinical trials evaluating HI-E, it is recommended that HI-E achievement requires not only transfusion independence but also an increase of Hb by at least
1.5 g/dL (5 0.9 mmol/L).
†As in IWG 2006 criteria, only RBC transfusions administered for an Hb level below 9 g/dL are taken into account. Exceptions to this rule may be accepted in cases of well-documented
moderate or severe angina pectoris, cardiac or pulmonary insufficiency, or ischemic neurologic diseases. In these cases, a higher transfusion trigger level may be established for an individual
patient. These patients may require special attention when analyzing responses within clinical trials. Transfusions for intercurrent diseases (bleeding, surgical procedure, etc) are not
considered.
‡Oscillations (eg, natural or due to drug intervals) within this period are accepted as long as the patient remains off any transfusions and the same transfusion policy has been maintained.
We suggest accepting 1 drop to an increase of between 1.0 and 1.5 g/dL over a period of 8 wk. We recommend that intervals between blood counts do not exceed 2 wk.
§Exceptions to this rule may be accepted in cases of well-documentedmoderate or severe angina pectoris, cardiac or pulmonary insufficiency, or ischemic neurologic diseases. In these cases,
a higher transfusion trigger level may be established for an individual patient. These patients may require special attention when analyzing responses within clinical trials. Transfusions for
intercurrent diseases (bleeding, surgical procedure, etc) should not be taken into account.
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Panel recommendation
We suggest that the current definition of loss of response (at
least a 50% decrement from maximum response levels in
neutrophils or platelets) is amended by the wording that the
patient should also not meet IWG response criteria anymore
(eg, ANC response from 0.5 to 1.2 and loss of response to 0.6
or platelet response from 30 to 70 and loss of response to 35)
all in the absence of dose interruptions and in the absence of
any infection, hemorrhagic events, and concomitant medi-
cations. The loss of erythroid response is currently well de-
fined but should be amended by the comment that, for
example, a response from Hb 8.5 to 13 and a consecutive
decline to 11.5 g/dL (ie, by.1.5 g/dL) is not a loss of response
whereas a decline to 9.5 or transfusion dependence is a loss of
response because the patient does notmeet response criteria
anymore when levels are compared with baseline. Further-
more, some HTB patients will not become completely TID
(eg, just a reduction by 50% of transfusion burden). As
a result, progression should be defined by an increase in
transfusion burden by at least 50% (eg, prior therapy 16 U
within 16 weeks, reduction to 8 U during therapy as a re-
sponse, and subsequent increase to 12 U).
As discussed in “1.2. Response evaluation,” we also emphasize
that dose adjustments and subsequent loss of hematologic
response need to be carefully evaluated (Table 1). In fact, if
a drug is stopped or its dose is reduced in a responding patient
for protocol-defined reasons (such as an adverse event) and if
this leads to a loss of response, this should not be counted as
relapse or progression, if reintroduction at the same or lower
dose of the drug induces a new response.
Conclusions
The IWG criteria modified in 2006 have been adopted in many
clinical trials and served as a valuable tool for the standardization
of clinically meaningful response measures in MDSs. Recent
experiences in lower-risk MDSs, however, show that there are
still some pitfalls when adopting these criteria, which can lead to
misinterpretation of outcome especially with regards to the
erythroid assessment. To overcome the pitfalls in some of the
IWG 2006 criteria as described herein, we suggest a review of
the current IWG response criteria, especially for HI-E response
evaluation. We have categorized this proposal into 3 parts: (1)
baseline assessments, (2) response evaluation, and (3) evaluation
of progression or relapse after HI. Tables 1-3 summarize novel
considerations by the steering committee with regard to
response and progression assessment. We believe that the
modifications (IWG 2018) presented here will allow for more
individualized pre- and on-study assessment and therefore
provide the MDS community with more accurate results in terms
Table 3. Suggested modified IWG 2018 HI-N and HI-P criteria for response evaluation
Newly suggested evaluations: IWG 2018 IWG 2006 criteria
Type of response Criteria Type of response Criteria
Platelet response
(pretreatment,
,1003 109/L), HI-P
• Absolute increase of 30 3 109/L for
patients starting with.203 109/L PLTs or
Platelet response (pretreatment,
,100 3 109/L), HI-P
• Absolute increase of 30 3 109/L for
patients starting with .20 3 109/L
PLTs or
• Increase from ,20 3 109/L to .20 3
10
9
/L and by at least 100%
• Increase from,203 109/L to.203 109/L
and by at least 100%
In addition,
• Evolution of bleeding symptoms is to be
taken into account
• Increments of platelets also for patients
with a pretreatment PLT count of.1003
109/L are to be reported
Dose-adjustment
policy for PLT
counts on treatment
• If the drug under investigation is being
stopped or its dose is being reduced in
a responding patient for protocol-defined
reasons leading to a loss of response, this
should not be counted as such, if
reintroduction at the same or lower dose
of the drug induces a new response
None
• When the investigational drug is stopped
or reduced in dose, weekly blood counts
are required to monitor the PLT levels
• 2 subsequent PLT counts .450 3 109/L
are a sufficient reason for treatment
discontinuation in the case of treatment
with TPO agonists
Neutrophil response
(pretreatment, all
patients), HI-N
At least 100% increase and an absolute
increase .0.5 3 109/L (pretreatment,
,1.0 3 109/L)
Neutrophil response (pretreatment,
,1.0 3 109/L), HI-N
At least 100% increase and an absolute
increase .0.5 3 109/L
Increments of neutrophils also for patients
with a pretreatment ANC of.1.03 109/L
are to be reported
ANC, absolute neutrophil count; PLT, platelet; TPO, thrombopoietin.
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of response evaluation. Although this work addresses “hema-
tological improvement” criteria, mainly concerning lower-risk
MDSs, we realize that CR, PR, and marrow CR may also have
to be reviewed in the future, especially for higher-risk MDS
patients treated with potentially disease-modifying treatments
like HMAs. Furthermore, future work will focus on the inte-
gration of patient-reported outcomes including QoL and
fatigue in response evaluation. This might be based on cur-
rently investigated models, such as the recently published
FA-IPSS(h).30
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